An observational study in ATTR-CM (Transthyretin Amyloid Cardiomyopathy), sponsored by Pfizer. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Pfizer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to assess the prognostic utility of various markers of disease progression among patients diagnosed with ATTR-CM treated with tafamidis utilizing Truveta database in the US. We will evaluate the impact of markers of disease progression (such as eGFR, ODI, NT-proBNP, NYHA and KCCQ) at Month 12 after initiation of tafamidis on clinical outcomes (including all-cause mortality, CV-related mortality, first CV hospitalization) among ATTR-CM patients treated with tafamidis in the US.
Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study will include patients with a documented dispensed fill of tafamidis within the Truveta database in the US from January 1, 2020 to the latest data available.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
Exclusion Criteria
Patients meeting any of the following criteria will not be included in the study:
ATTR-CM patients treated with tafamidis
Drug: Tafamidis
As provided in real-world routine clinical practice.
Time to All cause Mortality
Time frame: From Month 12 after tafamidis initiation through end of follow-up (up to 60+ months) (between July 1, 2019- June 30, 2026)
Time to Cardiovascular Mortality (CV)
Time frame: From Month 12 after tafamidis initiation through end of follow-up (up to 60+ months) (between July 1, 2019- June 30, 2026)
Time to First (Cardiovascular, Non-Cardiovascular) Hospitalization
Time frame: From Month 12 after tafamidis initiation through end of follow-up (up to 60+ months) (between July 1, 2019-June 30, 2026)
Change from Baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Time frame: Baseline, at diagnosis of ATTR-CM, at treatment initiation, and at Months (12,24,30,36,60)
Change from Baseline in Estimated glomerular filtration rate (eGFR)
Time frame: Baseline, at diagnosis of ATTR-CM, at treatment initiation, and at Months (12,24,30,36,60)
Change from Baseline in New York Heart Association classification (NYHA)
Time frame: Baseline, at diagnosis of ATTR-CM, at treatment initiation, and at Months (12,24,30,36,60)
Change from Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time frame: Baseline, at diagnosis of ATTR-CM, at treatment initiation, and at Months (12,24,30,36,60)
No study locations are listed for this record.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.